

## Editor

Tore K Kvien

## Associate Editors

Francis Berenbaum  
Hans Bijlsma  
David Pisetsky  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

## Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 9.111

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.  
Register using this QR code.

## Editorial

- 1281** Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox  
*M A González-Gay, C González-Juanatey*

## Viewpoint

- 1284** Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice  
*A G Semb, S Rollefstad, P van Riel, G D Kitas, E L Matteson, S E Gabriel*

## Review

- 1289** Imaging research results from the Osteoarthritis Initiative (OAI): a review and lessons learned 10 years after start of enrolment  
*F Eckstein, C K Kwok, T M Link, for the OAI investigators*

## Clinical and epidemiological research

- 1301** The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis  
*J Zhang, L Chen, E Delzell, P Muntner, W B Hillegeass, M M Safford, I Y N Millan, C S Crowson, J R Curtis*

- 1309** The global burden of neck pain: estimates from the Global Burden of Disease 2010 study  
*D Hoy, L March, A Woolf, F Blyth, P Brooks, E Smith, T Vos, J Barendregt, J Blore, C Murray, R Burstein, R Buchbinder*

- 1316** The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study  
*M Cross, E Smith, D Hoy, L Carmona, F Wolfe, T Vos, B Williams, S Gabriel, M Lassere, N Johns, R Buchbinder, A Woolf, L March*

- 1323** The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study  
*M Cross, E Smith, D Hoy, S Nolte, I Ackerman, M Fransen, L Bridgett, S Williams, F Guillemin, Catherine L Hill, L L Laslett, G Jones, F Cicuttini, R Osborne, T Vos, R Buchbinder, A Woolf, L March*

- 1331** Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy: 1-year data of the tREACH trial  
*P H de Jong, J M Hazes, H K Han, M Huisman, D van Zeben, P A van der Lubbe, A H Gerards, B van Schaeybroeck, P B de Sonnaville, M V van Krugten, J J Luime, A E Weel*

- 1340** Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study  
*J G Coghlan, C P Denton, E Grünig, D Bonderman, O Distler, D Khanna, U Müller-Ladner, J E Pope, M C Vonk, M Doelberg, H Chadha-Boreham, H Heinzl, D M Rosenberg, V V McLaughlin, J R Seibold, on behalf of the DETECT study group*

- 1350** Validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme  
*C Fernández-Espartero, E de Miguel, E Loza, E Tomero, M Gobbo, M A Descalzo, E Collantes-Estévez, J Mulero, S Muñoz-Fernández, P Zarco, L Carmona, ESPERANZA Study Group*

- 1356** A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study  
*L Heimans, K V C Wevers-de Boer, K Visser, R J Goekoop, M van Oosterhout, J B Harbers, C Bijkerk, I Speyer, M P D M de Bucke, P B J de Sonnaville, B A M Grillet, T W J Huizinga, C F Allaart*

- 1362** Health-related utility values of patients with primary Sjögren's syndrome and its predictors  
*D Lendrem, S Mitchell, P McMeeekin, S Bowman, E Price, C T Pease, P Emery, J Andrews, P Lanyon, J Hunter, M Gupta, M Bombardieri, N Sutcliffe, C Pitzalis, J McLaren, A Cooper, M Regan, I Giles, D Isenberg, S Vadivelu, D Coady, B Dasgupta, N McHugh, S Young-Min, R Moots, N Gendi, M Akil, B Griffiths, W-F Ng, on behalf of the UK primary Sjögren's Syndrome Registry*

- 1369** Three trajectories of activity limitations in early symptomatic knee osteoarthritis: a 5-year follow-up study  
*J F M Holla, M van der Leeden, M W Heymans, L D Roorda, S M A Bierma-Zeinstra, M Boers, W F Lems, M P M Steultjens, J Dekker*

- 1376** An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)  
*C A Langford, P A Monach, U Specks, P Seo, D Cuthbertson, C A McAlear, S R Ytterberg, G S Hoffman, J P Krischer, P A Merkel, for the Vasculitis Clinical Research Consortium*

- 1380** Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score  
*A Consolaro, N Ruperto, G Bracciolini, A Frisina, M C Gallo, A Pistorio, S Verazza, G Negro, V Cerloni, C Goldenstein-Schainberg, F Sztajnbock, N M Wulffraat, A Martini, A Ravelli, for the Paediatric Rheumatology International Trials Organization (PRINTO)*

- 1384** Smoking as a risk factor for the radiological severity of rheumatoid arthritis: a study on six cohorts  
*D P C de Rooy, J A B van Nies, M C Kapetanovic, H Kristjansdottir, M L E Andersson, K Forslund, D M F M van der Heijde, P K Gregersen, E Lindqvist, T W J Huizinga, G Gröndal, B Svensson, A H M van der Helm-van Mil*

## MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

C O P E COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>




When you have finished with this please recycle it

**1388** Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study  
*S Prieto-González, M Depétris, A García-Martínez, G Espígol-Frigolé, I Tavera-Bahillo, M Corbera-Bellata, E Planas-Rigol, M A Alba, J Hernández-Rodríguez, J M Grau, F Lomeña, M C Cid*

**1393** Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)  
*P M Meiners, A Vissink, F G M Kroese, F K L Spijkerkvet, N Sillevius Smitt-Kamminga, W H Abdulahad, J Bulthuis-Kuiper, E Brouwer, S Arends, H Bootsma*

## Basic and translational research

**1397** Disruption of Sirt1 in chondrocytes causes accelerated progression of osteoarthritis under mechanical stress and during ageing in mice  
*T Matsuzaki, T Matsushita, K Takayama, T Matsumoto, K Nishida, R Kuroda, M Kurosaka*

**1405**  Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence  
*R C Poulsen, A C Watts, R J Murphy, S J Snelling, A J Carr, P A Hulley*

**1414** Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps  
*F Pratesi, I Dioni, C Tommasi, M C Alcaro, I Paolini, F Barbetti, F Boscaro, F Panza, I Puxeddu, P Rovero, P Migliorini*

**1423** Smoking induces transcription of the heat shock protein system in the joints  
*C Ospelt, G G Camici, A Engler, C Kolling, A Vogetseder, R E Gay, B A Michel, S Gay*

## Letters

**1428** Towards an individualised target concentration of adalimumab in rheumatoid arthritis  
*E Ducourau, D Ternant, T Lequerré, P Fuzibet, X Le Loët, H Watier, P Goupille, G Paimtaud, O Vittecoq, D Mulleman*

**1429** A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab  
*M Ray, J R Curtis, J W Baddley*

**1430** The role of genetic polymorphisms regulating vitamin D levels in rheumatoid arthritis outcome: a Mendelian randomisation approach  
*S Viatte, A Yarwood, K McAllister, S Al-Mudhaffer, B Fu, E Flynn, D P M Symmons, A Young, A Barton*

**1433** GIMAP and Behçet disease: no association in the European population  
*L Ortiz-Fernández, M Conde-Jaldón, J R García-Lozano, M A Montes-Cano, N Ortego-Centeno, M J Castillo-Palma, G Espinosa, G Graña-Gil, J Sánchez-Bursón, M A González-Gay, A C Barnosi-Marin, R Solans, P Fanlo, M R Carballeira, T Camps, S Castañeda, J Martín, M F González-Escribano*

**1434** IgG4-related midline destructive lesion  
*E Della-Torre, H Mattoo, V S Mahajan, V Deshpande, D Krause, P Song, S Pillai, J H Stone*

**1436** *Coxiella burnetii* infection (Q fever) in rheumatoid arthritis patients with and without anti-TNF $\alpha$  therapy  
*T Schoffelen, L M Kampschreur, S E van Roeden, P C Wever, A A den Broeder, M H Nabuurs-Franssen, T Sprong, L A B Joosten, P L C M van Riel, J J Oosterheert, M van Deuren, M C W Creemers*

## Electronic pages

**e35** The classification criteria for Sjögren syndrome: issues for their improvement from the study of a large Italian cohort of patients  
*L Quartuccio, C Baldini, R Priori, E Bartoloni, F Carubbi, R Giacomelli, R Gerli, G Valesini, S De Vita, S Bombardieri*

**e36** Comments on recent advances and recommendations for the assessment of autoantibodies to cellular antigens referred as antinuclear antibodies  
*M Mahler, T Dervieux*

**e37** Survival analysis versus event count  
*L Arnaud, H Devilliers, Z Amoura*

**e38** Comment on: 'Spondyloarthritis: may the force be with you?', the editorial by McGonagle *et al*  
*L van Duivenvoorde, D Baeten*

**e39** Associations of CTX-II with biochemical markers of bone turnover raise questions about its tissue origin: new insights from CHECK  
*B de Klerk, F P J G Lafeber, W E van Spil*

**e40** What and what not to conclude from the results of the LEGS study?  
*A G Helg*

**e41** Response to A. G. Helg's comments on the LEGS study  
*M Fransen, R O Day*

**e42** The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans  
*A Alunno, F Carubbi, S Caterbi, O Bistoni, E Bartoloni, R Giacomelli, R Gerli*

**e43** The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans  
*X Lin, J Tian, K Rui, K-Y Ma, K-H Ko, S Wang, L Lu*

**e44** Comment on: 'Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry' by Sørensen *et al*  
*M Sykes, H Doll, K Gaffney*

**e45** Decreases in diagnostic delay are supported by sensitivity analyses  
*J Sørensen, M L Hetland*

**e46** The autoantibody repertoire in periodontitis: a role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis? Antibodies against uncitrullinated peptides seem to occur prior to the antibodies to the corresponding citrullinated peptides  
*M Brink, M Hansson, J Rönnelid, L Klareskog, S R Dahlqvist*

**e47** Response to: 'The autoantibody repertoire in periodontitis: a role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis? Antibodies against uncitrullinated peptides seem to occur prior to the antibodies to the corresponding citrullinated peptides' by Brink *et al*  
*P de Pablo, T Dietrich, I L C Chapple, M Milward, C D Buckley, P J Venables*